Total posts in Category: 30
CMT Summit + Retreat 2025: Uniting Patients, Researchers, Regulators, and Industry Leaders to...
Early preclinical research indicates that ALE2 could effectively slow or halt the progression of these debilitating symptoms, offering new hope for patients with these rare forms of CMT.
HNF Awards the inaugural HNF Clinical Translation Fellowship in the amount of $170,000 to Kayla...
Research Opportunity: CMT-SORD I am writing to you today because there is a research opportunity...
In the fast-paced world of para triathlons, one name stands out among the rest: Skyler Fisher, a dynamic 19-year-old powerhouse representing Team USA.
HNF Contributes CMTRN Data to C-Path’s RDCA-DAP, Strengthening Research Capabilities for Inherited...
HNF is thrilled to announce that we have been accepted to host a 1-hour panel discussion during the Bio International Convention in San Diego, CA, in June 2024.
"ABCs of CMT Pain Management" is now on Amazon! The Hereditary Neuropathy Foundation is thrilled...
Pediatric CMT Natural History Study enhancement to their Charcot-Marie-Tooth (CMT) and Inherited Neuropathies (IN) patient registry, Global Registry for Inherited Neuropathies (GRIN).
This year, HNF is spotlighting 3 Key Pillars vital to CMT Awareness & Research success.
We invite you to choose from each pillar throughout this September to drive Impact That Matters!
The Hereditary Neuropathy Foundation (HNF), an advocacy and research 501c3 non-profit, today...
Dtx today announced that the FDA has granted Orphan Drug Designation to DTx-1252, an investigational FALCON small interfering RNA (siRNA) therapeutic for the treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A).
Recent Comments